<DOC>
	<DOCNO>NCT00621036</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's cancer proteins may help body build effective immune response kill cancer cell . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving vaccine therapy together GM-CSF may make strong immune response kill cancer cell . PURPOSE : This phase II trial study side effect well give vaccine therapy together GM-CSF work treat patient CNS lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy GM-CSF Treating Patients With CNS Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine proportion patient CNS lymphoma develop anti-idiotype ( Id ) anti-keyhole limpet hemocyanin ( KLH ) humoral immune response serum and/or CSF follow patient-specific immunotherapy comprise recombinant tumor-derived immunoglobulin Id-KLH conjugate vaccine sargramostim ( GM-CSF ) . - To assess safety tolerability regimen patient . Secondary - To evaluate progression-free survival ( PFS ) patient treat regimen . - To determine time receipt first subsequent anti-lymphoma therapy initiate immunization Id-KLH conjugate vaccine . - To assess correlation anti-Id immune response CSF and/or serum PFS overall survival . Tertiary - To evaluate kinetics humoral immune response development patient treat regimen . OUTLINE : - Pre-immunotherapy : Patients submit tumor sample manufacturing idiotype ( Id ) -keyhole limpet hemocyanin ( KLH ) conjugate vaccine undergo placement Ommaya reservoir . Patients receive induction therapy comprise methotrexate IV every 2 week maximum radiographic response achieve , assess MRI brain . Patients receive methotrexate IV month 6 month . Patients leptomeningeal CSF involvement also receive intraventricular thiotepa twice week CSF clear three evaluation week CSF clear four evaluation . Patients 55 year age also undergo whole brain radiotherapy ( craniospinal radiotherapy extensive leptomeningeal disease present ) . Patients achieve stable response induction therapy proceed immunotherapy . - Immunotherapy : Patients receive recombinant tumor-derived immunoglobulin Id-KLH conjugate vaccine subcutaneously ( SC ) day 1 week 0 , 2 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 28 , 32 , 36 , 40 , 44 , 48 , 52 , 56 , 60 , 64 , 68 , 72 , 76 . Patients also receive sargramostim ( GM-CSF ) SC day 1-4 week Id-KLH conjugate vaccine . After completion therapy , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically CSF cytologically confirm CNS lymphoma follow clinical history : Primary CNS lymphoma initial diagnosis Primary CNS lymphoma relapse Systemic lymphoma CNS disease initial diagnosis relapse Adequate fresh tissue cell pellet available analysis Genitope Corporation determine adequacy idiotype ( Id ) manufacture Tumor must express functional light heavy chain gene No tumor know find surface immunoglobulin negative Not leukemic phase ( i.e. , &gt; 5,000/mm³ circulate tumor cell ) PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 70100 % WBC ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ Hemoglobin ≥ 10 g/dL Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( unless due Gilbert 's disease ) Creatinine ≤ 1.5 time ULN Able undergo placement Ommaya reservoir Able receive induction therapy ( chemotherapy without brain radiotherapy ) intent induce remission Speaks English Spanish No malignancy within past 3 year , except adequately treat basal cell squamous cell carcinoma skin cervical carcinoma situ Not pregnant nursing No immunosuppressive viral infection evidence HIV antibody antigen , hepatitis B antigen , hepatitis C antibody antigen positivity No history autoimmune disease require treatment within past 5 year , include previously treat autoimmune hemolytic anemia immune thrombocytopenia PRIOR CONCURRENT THERAPY : More 30 day since prior concurrent participation another therapeutic clinical trial More 2 week since prior steroid No concurrent immunosuppressive , include corticosteroid Transient use optical nasal steroid solution allow No concurrent anticancer therapy therapy nonHodgkin lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
</DOC>